B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20

References

• Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176–1180. doi:10.1001/archneurol.2012.314
   PubMedGoogle Scholar
• Levy M, Wildemann B, Jarius S, et al. Immunopathogenesis of neuromyelitis optica. Adv Immunol. 2014;121:213–242. doi:10.1016/B978-0-12-800100-4.00006-4
   PubMed Web of Science ®Google Scholar
• Kowarik MC, Astling D, Gasperi C, et al. CNS aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol. 2017;4(6):369–380. eCollection 2017 Jun. doi:10.1002/acn3.418
   Web of Science ®Google Scholar
• Mealy MA, Mossburg SE, Kim SH, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord. 2019;28:64–68. Epub 2018 Dec 9. doi:10.1016/j.msard.2018.12.011
   Web of Science ®Google Scholar
• Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e468. eCollection 2018 Jul. doi:10.1212/NXI.0000000000000468
   Web of Science ®Google Scholar
• Rituxan (rituximab) [package insert]. South San Francisco, CA: Genentech, Inc.; Revised February 2010.
   Google Scholar
• Bar-Or A, Calabresi PAJ, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann Neurol. 2008;63(3):395–400. doi:10.1002/ana.21363
   PubMed Web of Science ®Google Scholar
• Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342–1348. doi:10.1001/jamaneurol.2016.1637
   PubMed Web of Science ®Google Scholar
• Ancau M, Berthele A, Hemmer B. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opin Biol Ther. 2019;19(8):829–843. Epub 2019 May 24. doi:10.1080/14712598.2019.1611778
   PubMed Web of Science ®Google Scholar
• Kimbrough D, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1(4):180–187. doi:10.1016/j.msard.2012.06.002
   PubMed Web of Science ®Google Scholar
• Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270–1272. doi:10.1212/01.WNL.0000159399.81861.D5
   PubMed Web of Science ®Google Scholar
• Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003–2009. Epub 2017 Aug 22. doi:10.1007/s00415-017-8590-0
   PubMed Web of Science ®Google Scholar
• Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 Study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306. Epub 2020 Mar 18. doi:10.1016/S1474-4422(20)30066-1
   PubMed Web of Science ®Google Scholar
• Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019;19(1):36. doi:10.1186/s12883-019-1261-2
   PubMed Web of Science ®Google Scholar
• Annovazzi P, Capobianco M, Moiola L, et al. Rituximab in the treatment of neuromyelitis optica: a multicentre Italian Observational Study. J Neurol. 2016;263(9):1727–1735. Epub 2016 Jun 10. doi:10.1007/s00415-016-8188-y
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324–330. doi:10.1001/jamaneurol.2013.5699
   PubMed Web of Science ®Google Scholar
• OCREVUS (ocrelizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; March 2017.
   Google Scholar
• Ng HS, Rosenbult CL, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opin Drug Saf. 2020;19(9):1069–1094. Epub 2020 Aug 31. doi:10.1080/14740338.2020.1807002
   PubMed Web of Science ®Google Scholar
• Patel A, Sul J, Gordon ML, et al. Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol. 2021;78:e210627. Online ahead of print. doi:10.1001/jamaneurol.2021.0627
   Web of Science ®Google Scholar
• Stamatellos VP, Siafis S, Papazisis G. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: a disproportionality analysis using US food and drug administration adverse event reporting system (FAERS) database. Br J Clin Pharmacol. 2021. Online ahead of print. doi:10.1111/bcp.14916.
   Web of Science ®Google Scholar
• Caldito NG, Shirani A, Salter A, et al. Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA adverse event reporting database. Mult Scler. 2021;27(7):1066–1076. Epub 2020 Aug 21. doi:10.1177/1352458520949986
   PubMed Web of Science ®Google Scholar
• KESIMPTA (ofatumumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2020.
   Google Scholar
• Hauser SL, Kappos L, Arnold DL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95(13):e1854–e1867. Epub 2020 Jul 20. doi:10.1212/WNL.0000000000010376
   PubMed Web of Science ®Google Scholar
• Maillart E, Renaldo F, Papeix C, et al. Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e683. Print 2020 May. doi:10.1212/NXI.0000000000000683
   Web of Science ®Google Scholar
• Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420–429. Epub 2020 Apr 30. doi:10.1177/1352458520918375
   PubMed Web of Science ®Google Scholar
• Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019;98(25):e15944. doi:10.1097/MD.0000000000015944
   PubMed Web of Science ®Google Scholar
• UPLIZNA (inebilizumab-cdon) [package insert]. Gaithersburg, MD: Viela Bio, Inc.; June 2020.
   Google Scholar
• Chen D, Gallagher S, Monson NL, et al. Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med. 2016;5(12):107. doi:10.3390/jcm5120107
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363. Epub 2019 Sep 5. doi:10.1016/S0140-6736(19)31817-3
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Weinshenker BG, et al. Long-term efficacy outcomes with inebilizumab treatment in neuromyelitis optica spectrum disorder: the N-MOmentum trial. Poster presented at: American Academy of Neurology Annual Meeting; April 17–21; 2021; virtual.
   Google Scholar
• Cree BAC, Bennett JL, Weinshenker BG, et al. Long-term safety outcomes with inebilizumab treatment in neuromyelitis optica spectrum disorder: the N-MOmentum trial. Poster presented at: American Academy of Neurology Annual Meeting; April 17–21; 2021; virtual.
   Google Scholar
• Tullman M, Ratchford J, She D. Evaluation of infusion reactions and infusion times in the N-MOmentum study of inebilizumab for NMOSD. Poster presented at: ACTRIMS Forum; February 25–27; 2021; virtual.
   Google Scholar
• Narayan R, Simpson A, Fritsche K, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66–72. Epub 2018 Jul 24. doi:10.1016/j.msard.2018.07.025
   PubMed Web of Science ®Google Scholar
• Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251. Epub 2020 Jun 2. doi:10.1016/j.msard.2020.102251
   PubMed Web of Science ®Google Scholar
• Pittock S, Paul F, Marignier R, et al. AQP4-IgG seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Poster presented at: Annual ECTRIMS Congress; September 9–12; 2020; virtual.
   Google Scholar